COMMUNIQUÉS West-GlobeNewswire

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
08/07/2024
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, [...]
Novo Nordisk A/S - share repurchase programme
08/07/2024
Bagsværd, Denmark, 08 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Hapbee Announces Initial Closing of Non-Brokered Private Placement of $2.7 Million
08/07/2024
MONTREAL, July 08, 2024 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or the “Company”), the Canadian-based wearable, wellness technology company and creator of the [...]
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
08/07/2024
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million [...]
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
08/07/2024
Jeff Wade Named President and Chief Operating Officer THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has [...]
Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer
08/07/2024
– Dr. Wright has three decades of experience in the research and development of viral vectors and has been involved in the development of multiple approved gene therapies globally – PALO ALTO, Calif. and RESEARCH [...]
GRI Bio Regains Compliance with Nasdaq
08/07/2024
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the [...]
Courage in the Ring: MS Patient Fights for a Cure
08/07/2024
LONDON, Ontario, July 08, 2024 (GLOBE NEWSWIRE) -- Meet Julia Campbell, a resilient patient confronting multiple sclerosis (MS) head on since her diagnosis early last year. Despite the challenges she’s faced, Julia [...]
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
08/07/2024
MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing
08/07/2024
GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today [...]
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
08/07/2024
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
08/07/2024
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus [...]
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
08/07/2024
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab [...]
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
08/07/2024
Publication of data relating to RenovoRx’s targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal LOS ALTOS, Calif., July [...]
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
08/07/2024
According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a [...]
Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
08/07/2024
The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/07/2024
PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that [...]
Monthly information on share capital and company voting rights
05/07/2024
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/07/2024
BRISBANE, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards [...]

Pages